By Anna Rose Welch, chief editor, Biosimilar Development
During our conversation, Pontchartrain Cancer Center COO Kathy Oubre shared what biosimilar makers can do to balance promoting sustainability and cost savings while also supporting cancer centers and their healthcare professionals
By Stanton R. Mehr, content director, Biosimilars Review & Report
Five years after the first biosimilar was made available for prescription in the U.S., the American biosimilar market may be turning a corner on the road to sustainability.
This article provides general guidance on how to convert an existing ELISA assay to a Biacore SPR-assay, and, by doing so, shows how you can get results in less than half the time compared with ELISA.
